Yes I have been trying to find out from anyone knowledgeable in the process as to how difficult it would be for Amain’s AG to compete for “shelf space” at the pharmacy level.
On your other point though, i am guessing that in order to make those deals with insurers that they have, they are basically offering V at a generic price already.
Birdbrain ideas, I know KM stated he will release an AG if and when necessary. I just don’t know what metrics are involved in that decision so it tells me little about what trigger would cause them to do that. I can’t imagine what they’re waiting for at this point. AMRN should’ve launched an AG soon after losing marine patents IMO. For some unknown reason AMRN chose not to. You brought up an interesting question. I hadn’t considered that AMRN could release an AG of their own or partner with somebody to release an AG, and still keep the Brand V in the market.. it turns out AMRN can do both. The brand product doesn’t have to go away. This link answers some of your questions.
Market Data 
Markets 
AI
